SPRY — ARS Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1671858 ·
Last close
$5.35
Market Cap
$532.04M
52W High
$10.87
52W Low
$4.91
ADV30
2,319,945
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 22,681,000 | 16,395,000 | -60,145,000 | -60,618,000 | 287,571,000 | 24,321,000 | 226,263,000 |
| Dec 2025 | 28,087,000 | 21,933,000 | -41,465,000 | -41,324,000 | 327,652,000 | 41,317,000 | 213,394,000 |
| Sep 2025 | 32,501,000 | 24,310,000 | -53,192,000 | -51,151,000 | 372,803,000 | 59,557,000 | 225,148,000 |
| Jun 2025 | 15,717,000 | 10,733,000 | -47,614,000 | -44,883,000 | 313,472,000 | 51,540,000 | 121,151,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-175,070,000
Investing CF
$55,495,000
Financing CF
$104,032,000
CapEx
$-641,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.94
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-355,221,000
Inventory
$8,817,000
Receivables
$28,662,000
ST Investments
$176,648,000
EBIT TTM
$-189,779,000
Pretax Income TTM
$-198,056,000
Interest Exp TTM
$2,441,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$116,927,000
EBITDA
$-214,646,000
Free Cash Flow
$-117,704,248
Enterprise Value
$559,801,280
Total Cash
$143,844,992
Total Debt
$171,603,008
Shares Out
99,447,343
Trailing EPS
$-2.12
Book Value
$0.13
ROE
-210.3%
ROA
-48.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 84,278,000 | -179,448,000 | -171,298,000 | 327,652,000 | 213,394,000 | — | -170,866,000 |
| Dec 2024 | 89,149,000 | -3,083,000 | 7,998,000 | 351,153,000 | 94,355,000 | — | 13,548,000 |
| Dec 2023 | 30,000 | -67,520,000 | -54,365,000 | 233,188,000 | 2,428,000 | — | -59,266,000 |
| Dec 2022 | 1,316,000 | -35,516,000 | -34,682,000 | 281,435,000 | 8,549,000 | — | -40,078,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.89
Max Pain — expiry 2026-09-18
max pain strike: $5.00 · spot: $5.55 · call oi: 3,114 · put oi: 682
Expected Move to 2026-09-18:
±$1.02
(18.47%) —
implied range
$4.53 –
$6.58
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VREOF | Vireo Growth Inc. | $523.26M | $10.89 | — |
| CTNM | Contineum Therapeutics, Inc. | $548.10M | $16.63 | — |
| OVID | Ovid Therapeutics Inc. | $550.74M | $2.82 | — |
| EVMN | Evommune, Inc. | $496.11M | $13.67 | — |
| MPLT | MapLight Therapeutics, Inc. | $495.87M | $11.36 | — |
News headlines (Yahoo Finance, 1h cache)
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
2026-08-20 13:55 · Yahoo
ARS Pharmaceuticals Q2 Earnings Call Highlights
2026-08-14 03:04 · Yahoo
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 21:35 · Yahoo
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
2026-08-13 20:01 · Yahoo
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
2026-08-03 11:30 · Yahoo
ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO
2026-07-15 15:42 · Yahoo
ARS Pharmaceuticals Announces CEO Succession
2026-07-07 20:30 · Yahoo
ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices
2026-06-29 02:06 · Yahoo
ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January
2026-06-25 20:57 · Yahoo
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today
2026-06-25 01:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.